Long-Term Follow-Up of Inpatients with Failed Back Surgery Syndrome Who Received Integrative Korean Medicine Treatment: A Retrospective Analysis and Questionnaire Survey Study

Abstract

Introduction: this study aimed to investigate the long-term clinical efficacy and satisfaction degree of integrative Korean medicine (KM) treatment for patients with failed back surgery syndrome (FBSS). Methods: we performed a follow-up questionnaire survey and retrospective analysis of medical records for patients with FBSS who underwent inpatient treatment for ≥ 1 week. The primary evaluation indices were numeric rating scale (NRS) scores for low back pain (LBP) and leg pain at admission and discharge. Sub-evaluation indices included the Oswestry Disability Index (ODI) and EuroQol 5-dimension (EQ-5D) score. The follow-up questionnaire survey obtained information regarding previous surgeries; reasons for satisfaction/dissatisfaction with surgical and KM treatment; and current status. Results: compared with at admission, there was a significant post-treatment decrease in the NRS scores for LBP and leg pain, as well as the ODI score. Further, there was a significant post-treatment increase in the EQ-5D score. Regarding the patients’ global impression of change for KM treatment administered during admission and at the follow-up questionnaire survey, 101 (95.3%) patients selected “minimally improved” or better. Conclusion: integrative KM treatment could effectively reduce pain, as well as improve function and health-related quality of life, in patients with FBSS.

Effects of the administration of Shinbaro 2 in a rat lumbar disk herniation model

“…The formulation has also shown protective effects against nerve injury and osteoarthritis in preclinical studies (29,30). Clinical trials found that Shinbaro 2 was efficacious against spine disease, including disk herniation and spinal stenosis, with a generally safe profile under long-term use (27,31). However, previous studies have not examined the effects of Shinbaro 2 on various molecular markers of LDH in vivo.…”

Understanding exosomes: Part 2—Emerging leaders in regenerative medicine

“…1157,1158 According to epidemiological data, 80% of individuals will, at some point in their lives, have lower back discomfort. 1159 LBP is thought to be one of the main factors limiting the amount of labor that individuals under 45 may be capable of. 1160,1161 In the United States, the direct cost of treating LBP is estimated to be over 30 billion US dollars, while the indirect socioeconomic losses are estimated to be around 100 billion US dollars.…”

Mesenchymal Stem Cell-Derived Exosomes as a Novel Strategy for the Treatment of Intervertebral Disc Degeneration

“…At present, IVDD therapy generally includes conservative symptomatic and surgical treatments ( Park et al, 2021 ). Conservative treatment usually exhibits good results for LBP ( van Middelkoop et al, 2011 ; Quentin et al, 2021 ).…”

“…Low back pain (LBP) is a widespread health concern in modern society, resulting in high socioeconomic consequences ( Katz, 2006 ; Kague et al, 2021 ). Epidemiological statistics show that approximately 80% of adults experience lower back pain at least once in their lifetime ( Park et al, 2021 ); LBP is considered to be one of the most important reasons that limit the working capacity of people younger than 45 years ( Deyo and Weinstein, 2001 ; Balague et al, 2012 ). Annually, the direct cost of treating LBP is approximately US$ 30 billion and the indirect socio-economic losses account for approximately US$ 100 billion in the United States ( Binch et al, 2021 ).…”